A	O
phase	B-study_type
2	I-study_type
study	I-study_type
of	O
an	O
oral	O
mTORC1	B-arm_description
/	I-arm_description
mTORC2	I-arm_description
kinase	I-arm_description
inhibitor	I-arm_description
(	O
CC-223	O
)	O
for	O
non	O
-	O
pancreatic	O
neuroendocrine	O
tumors	O
with	O
or	O
without	O
carcinoid	O
symptoms	O

A	O
phase	B-study_type
2	I-study_type
study	I-study_type
of	O
an	O
oral	O
mTORC1	B-arm_description
/	I-arm_description
mTORC2	I-arm_description
kinase	I-arm_description
inhibitor	I-arm_description
(	O
CC-223	O
)	O
for	O
non	O
-	O
pancreatic	O
neuroendocrine	O
tumors	O
with	O
or	O
without	O
carcinoid	O
symptoms	O

A	O
phase	B-study_type
2	I-study_type
study	I-study_type
of	O
an	O
oral	O
mTORC1	B-arm_description
/	I-arm_description
mTORC2	I-arm_description
kinase	I-arm_description
inhibitor	I-arm_description
(	O
CC-223	O
)	O
for	O
non	O
-	O
pancreatic	O
neuroendocrine	O
tumors	O
with	O
or	O
without	O
carcinoid	O
symptoms	O
EdwardWolin	B-authors
edward.wolin@mssm.edu	O

UNITED	O
STATES	O
University	O
of	O
Wisconsin	O
-Madison	O
UNITED	O
STATES	O
UNITED	O
STATES	O
A	O
phase	B-study_type
2	I-study_type
study	I-study_type
of	O
an	O
oral	O
mTORC1	B-arm_description
/	I-arm_description
mTORC2	I-arm_description
kinase	I-arm_description
inhibitor	I-arm_description
(	O
CC-223	O
)	O
for	O
non	O
-	O
pancreatic	O
neuroendocrine	O
tumors	O
with	O
or	O
without	O
carcinoid	O
symptoms	O
September	O
17	O
,	O
2019	O
September	O
17	O
,	O
2019	O
September	O
17	O
,	O
2019	O
10.1371	O
/	O
journal.pone.0221994	O
Received	O
:	O
December	O
3	O
,	O
2018	O
Accepted	O
:	O
July	O
20	O
,	O
2019	O

Neuroendocrine	O
tumors	O
(	O
NET	O
)	O
,	O
although	O
generally	O
believed	O
to	O
be	O
uncommon	O
,	O
are	O
the	O
second	O
most	O
common	O
gastrointestinal	O
(	O
GI	O
)	O
malignancy	O
,	O
superseded	O
only	O
by	O
colorectal	O
neoplasias	O
[	O
1,2	O
]	O
.	O
This	O
malignancy	O
is	O
reported	O
to	O
be	O
increasing	O
in	O
prevalence	O
,	O
with	O
the	O
greatest	O
increase	O
in	O
lung	O
,	O
small	O
intestine	O
,	O
and	O
rectal	O
NETs	O
[	O
1	O
]	O
.	O
Although	O
survival	O
has	O
improved	O
with	O
introduction	O
of	O
newer	O
therapies	O
,	O
prognosis	O
for	O
patients	O
with	O
advanced	O
disease	O
remains	O
poor	O
[	O
1	O
]	O
.	O

The	O
phosphatidylinositol-4,5-bisphosphate	O
3-kinase	O
(	O
PI3K)-protein	O
kinase	O
B	O
(	O
AKT)-mammalian	O
target	O
of	O
rapamycin	O
(	O
mTOR	O
)	O
signalling	O
pathway	O
,	O
which	O
is	O
inappropriately	O
activated	O
in	O
many	O
cancers	O
,	O
plays	O
a	O
central	O
role	O
in	O
the	O
genesis	O
and	O
progression	O
of	O
NET	O
.	O
The	O
mTOR	O
complex	O
1	O
(	O
mTORC1	O
)	O
inhibitor	O
everolimus	O
has	O
become	O
well	O
-	O
established	O
as	O
an	O
effective	O
therapy	O
for	O
NET	O
arising	O
from	O
the	O
pancreas	O
,	O
lung	O
,	O
or	O
GI	O
tract	O
,	O
with	O
an	O
associated	O
median	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
of	O
11.0	O
months	O
[	O
3,4	O
]	O
.	O
mTOR	O
kinase	O
is	O
a	O
serine	O
/	O
threonine	O
kinase	O
that	O
serves	O
as	O
a	O
core	O
component	O
of	O
two	O
complexes	O
;	O
mTORC1	O
and	O
mTORC2	O
.	O
The	O
former	O
modulates	O
cell	O
proliferation	O
via	O
phosphorylation	O
of	O
eukaryotic	O
translation	O
initiation	O
factor	O
4E	O
binding	O
protein	O
1	O
(	O
4E	O
-	O
BP1	O
)	O
and	O
p70	O
ribosomal	O
S6	O
kinase	O
1	O
(	O
S6K1	O
)	O
,	O
whereas	O
the	O
latter	O
acts	O
via	O
phosphorylation	O
of	O
AKT	O
[	O
5	O
]	O
.	O
Everolimus	O
inhibits	O
the	O
mTORC1	O
complex	O
but	O
may	O
upregulate	O
mTORC2	O
,	O
which	O
thus	O
maintains	O
AKT	O
activation	O
.	O
Consequently	O
,	O
inhibitors	O
that	O
can	O
target	O
both	O
complexes	O
may	O
offer	O
clinical	O
advantages	O
in	O
terms	O
of	O
improved	O
efficacy	O
[	O
5][6][7][8][9][10	O
]	O
.	O

CC-223	O
is	O
an	O
inhibitor	O
of	O
TOR	O
kinase	O
in	O
mTORC1	O
and	O
mTORC2	O
that	O
is	O
known	O
to	O
overcome	O
mTORC2	O
feedback	O
pathway	O
upregulation	O
and	O
thus	O
potentially	O
minimize	O
development	O
of	O
therapy	O
resistance	O
due	O
to	O
increased	O
phosphorylation	O
of	O
AKT	O
[	O
11	O
]	O
.	O
In	O
non	O
-	O
clinical	O
studies	O
,	O
inhibition	O
of	O
mTORC1	O
and	O
mTORC2	O
leads	O
to	O
more	O
effective	O
inhibition	O
of	O
cancer	O
cell	O
proliferation	O
than	O
does	O
blocking	O
mTORC1	O
alone	O
[	O
11	O
]	O
.	O
In	O
mice	O
bearing	O
human	O
carcinoid	O
xenografts	O
that	O
secrete	O
serotonin	O
,	O
tumors	O
that	O
progressed	O
on	O
rapamycin	O
remained	O
stable	O
or	O
decreased	O
in	O
volume	O
from	O
baseline	O
after	O
treatment	O
with	O
CC-223	O
[	O
12	O
]	O
.	O

In	O
a	O
first	O
-	O
in	B-study_type
-	I-study_type
human	I-study_type
study	I-study_type
,	O
CC-223	B-arm_description
was	O
evaluated	O
as	O
a	O
treatment	O
for	O
patients	O
with	O
advanced	O
solid	O
tumors	O
,	O
and	O
the	O
45	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
d	I-arm_dosage
dose	O
was	O
established	O
as	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
[	O
13	O
]	O
.	O
Here	O
,	O
we	O
report	O
results	O
of	O
an	O
expansion	B-study_type
cohort	I-study_type
in	O
patients	O
with	O
non	O
-	O
pancreatic	O
GI	O
or	O
unknown	O
primary	O
NET	O
treated	O
at	O
the	O
previously	O
-	O
established	O
MTD	O
or	O
lower	O
dose	O
if	O
needed	O
.	O

Using	O
the	O
optimal	O
CC-223	B-arm_description
dose	O
of	O
45	B-arm_dosage
mg	I-arm_dosage
established	O
in	O
phase	O
1	O
[	O
13	O
]	O
,	O
cohort	B-study_type
expansion	I-study_type
objectives	O
were	O
to	O
determine	O
the	O
tolerability	O
of	O
CC-223	B-arm_description
,	O
characterize	O
the	O
pharmacokinetic	O
(	O
PK	O
)	O
and	O
pharmacodynamic	O
(	O
biomarker	O
)	O
profiles	O
,	O
and	O
identify	O
a	O
preliminary	O
efficacy	O
signal	O
in	O
seven	O
parallel	O
cohorts	O
of	O
various	O
preselected	O
tumor	O
types	O
;	O
only	O
the	O
NET	O
cohorts	O
are	O
reported	O
here	O
.	O
Patient	O
flow	O
is	O
shown	O
in	O
Fig	O
1	O
.	O
The	O
study	O
(	O
NCT01177397	O
)	O
was	O
conducted	O
in	O
accordance	O
with	O
the	O
International	O
Conference	O
on	O
Harmonisation	O
(	O
ICH	O
)	O
E6	O
requirements	O
for	O
Good	O
Clinical	O
Practice	O
,	O
in	O
accordance	O
with	O
the	O
ethical	O
principles	O
outlined	O
in	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
according	O
to	O
all	O
other	O
national	O
and	O
institutional	O
guidelines	O
.	O
The	O
study	O
protocol	O
was	O
approved	O
by	O
the	O
institutional	O
review	O
boards	O
and	O
other	O
necessary	O
oversight	O
committees	O
at	O
each	O
investigational	O
site	O
(	O

CC-223	B-arm_description
capsules	O
were	O
taken	O
orally	B-arm_dosage
once	I-arm_dosage
daily	I-arm_dosage
in	I-arm_dosage
continuous	I-arm_dosage
28-day	I-arm_dosage
cycles	I-arm_dosage
.	O
An	O
initial	O
cohort	O
started	O
CC-223	B-arm_description
at	O
a	O
dose	O
of	O
45	B-arm_dosage
mg	I-arm_dosage
;	O
this	O
was	O
the	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
established	O
in	O
phase	O
1	O
but	O
,	O
after	O
observing	O
a	O
high	O
rate	O
of	O
dose	O
adjustments	O
due	O
to	O
toxicity	O
among	O
patients	O
with	O
NET	O
,	O
a	O
second	O
cohort	O
started	O
CC-223	B-arm_description
at	O
30	B-arm_dosage
mg	I-arm_dosage
.	O
To	O
mitigate	O
toxicity	O
,	O
dosage	O
could	O
be	O
adjusted	O
with	O
either	O
short	O
interruptions	O
,	O
dose	O
level	O
reductions	O
,	O
or	O
every	O
-	O
other	O
-	O
day	O
administration	O
.	O
Treatment	O
was	O
permanently	O
discontinued	O
for	O
disease	O
progression	O
,	O
unmanageable	O
toxicity	O
,	O
patient	O
withdrawal	O
of	O
consent	O
,	O
or	O
other	O
reasons	O
specified	O
by	O
the	O
protocol	O
as	O
requiring	O
study	O
withdrawal	O
.	O

Baseline	O
assessments	O
were	O
completed	O
within	O
28	O
days	O
prior	O
to	O
first	O
dose	O
of	O
CC-223	B-arm_description
.	O
Drug	O
tolerability	O
was	O
continuously	O
evaluated	O
until	O
28	O
days	O
after	O
the	O
last	O
dose	O
,	O
using	O
clinical	O
event	O
and	O
laboratory	O
test	O
monitoring	O
comprising	O
a	O
conventional	O
hematologic	O
and	O
coagulation	O
(	O
if	O
taking	O
anti	O
-	O
coagulants	O
)	O
panel	O
;	O
serum	O
electrolytes	O
;	O
fasting	O
blood	O
glucose	O
(	O
this	O
also	O
included	O
daily	O
selfmonitoring	O
with	O
finger	O
stick	O
samples	O
for	O
the	O
first	O
month	O
and	O
for	O
longer	O
if	O
necessary	O
)	O
,	O
HbA	O
1c	O
,	O
insulin	O
,	O
and	O
c	O
-	O
peptide	O
;	O
liver	O
enzymes	O
;	O
serum	O
creatinine	O
;	O
and	O
protein	O
.	O
Others	O
included	O
serum	O
uric	O
acid	O
,	O
amylase	O
and	O
lipase	O
,	O
lipoproteins	O
,	O
thyroid	O
function	O
tests	O
,	O
creatine	O
kinase	O
,	O
and	O
immunoglobulins	O
including	O
T	O
-	O
cell	O
subsets	O
(	O
CD4	O
+	O
and	O
CD8	O
+	O
)	O
.	O
We	O
also	O
performed	O
serial	O
triplicate	O
electrocardiograms	O
(	O
ECGs	O
)	O
,	O
periodic	O
left	O
ventricular	O
ejection	O
fraction	O
estimations	O
(	O
echo	O
or	O
multiple	O
gated	O
acquisition	O
[	O
MUGA	O
]	O
)	O
,	O
regular	O
physical	O
exams	O
and	O
vital	O
sign	O
measurements	O
(	O
heart	O
rate	O
,	O
blood	O
pressure	O
,	O
respiratory	O
rate	O
,	O
and	O
temperature	O
)	O
.	O
Adverse	O
events	O
were	O
coded	O
with	O
Medical	O
Dictionary	O
for	O
Regulatory	O
Activities	O
(	O
MedDRA	O
)	O
version	O
19.0	O
.	O
Severity	O
of	O
adverse	O
events	O
was	O
classified	O
using	O
the	O
National	O
Cancer	O
Institute	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
(	O
CTCAE	O
)	O
version	O
4.0	O
.	O
A	O
safety	O
review	O
committee	O
provided	O
study	O
oversight	O
.	O

Tumors	O
were	O
restaged	O
by	O
the	O
principal	O
investigator	O
at	O
each	O
site	O
using	O
computed	O
tomography	O
(	O
CT	O
)	O
,	O
positron	O
emission	O
tomography	O
(	O
PET)-CT	O
,	O
or	O
magnetic	O
resonance	O
imaging	O
scans	O
after	O
every	O
2	O
cycles	O
through	O
cycle	O
6	O
,	O
and	O
every	O
3	O
cycles	O
thereafter	O
,	O
using	O
Response	O
Evaluation	O
Criteria	O
In	O
Solid	O
Tumors	O
(	O
RECIST	O
)	O
version	O
1.1	O
criteria	O
for	O
response	O
[	O
14	O
]	O
.	O

Metabolic	O
changes	O
were	O
assessed	O
by	O
percent	O
change	O
in	O
total	O
of	O
standardized	O
uptake	O
value	O
(	O
SUV	O
)	O
of	O
2	O
-	O
18	O
F	O
-	O
fluoro-2-deoxyglucose	O
(	O
FDG	O
)	O
with	O
PET	O
scanning	O
from	O
baseline	O
to	O
day	O
15	O
in	O
cycle	O
1	O
.	O
Carcinoid	O
symptoms	O
of	O
flushing	O
and	O
diarrhea	O
were	O
documented	O
monthly	O
with	O
a	O
non-	O
https://doi.org/10.1371/journal.pone.0221994.g001	O
validated	O
symptom	O
questionnaire	O
that	O
was	O
completed	O
at	O
each	O
study	O
visit	O
.	O
Patients	O
reported	O
whether	O
they	O
had	O
experienced	O
specific	O
events	O
,	O
and	O
the	O
severity	O
and/or	O
frequency	O
of	O
these	O
events	O
.	O
Symptom	O
improvement	O
was	O
defined	O
as	O
�	O
50	O
%	O
reduction	O
in	O
frequency	O
and/or	O
a	O
1-grade	O
reduction	O
in	O
severity	O
for	O
each	O
from	O
baseline	O
.	O

Central	O
laboratories	O
conducted	O
serial	O
stimulated	O
blood	O
biomarker	O
assays	O
in	O
monocytes	O
(	O
CD14	O
+	O
)	O
for	O
p4E	O
-	O
BP1	O
and	O
pPKB	O
(	O
also	O
known	O
as	O
pAKT	O
)	O
for	O
assessment	O
of	O
mTORC1	O
and	O
mTORC2	O
inhibition	O
,	O
respectively	O
.	O
Monthly	O
changes	O
from	O
baseline	O
for	O
chromogranin	O
A	O
(	O
CgA	O
)	O
,	O
and	O
for	O
other	O
serum	O
hormones	O
if	O
elevated	O
,	O
were	O
assayed	O
locally	O
.	O

Blood	O
for	O
PK	O
analysis	O
was	O
drawn	O
on	O
day	O
1	O
pre	O
-	O
dose	O
and	O
for	O
up	O
to	O
48	O
hours	O
post	O
-	O
dose	O
,	O
and	O
then	O
on	O
day	O
15	O
up	O
to	O
8	O
hours	O
post	O
-	O
dose	O
.	O
Urine	O
on	O
day	O
1	O
was	O
collected	O
within	O
30	O
minutes	O
prior	O
to	O
dosing	O
and	O
at	O
intervals	O
up	O
to	O
24	O
hours	O
post	O
-	O
dose	O
.	O
Samples	O
were	O
assayed	O
for	O
CC-223	B-arm_description
and	O
the	O
principal	O
active	O
metabolite	O
(	O
M1	O
)	O
using	O
validated	O
chiral	O
liquid	O
chromatography	O
mass	O
spectrometry	O
.	O
CC-223	B-arm_description
PK	O
parameters	O
were	O
calculated	O
using	O
dosing	O
and	O
sample	O
collection	O
times	O
.	O
Noncompartmental	O
PK	O
analysis	O
was	O
performed	O
used	O
WinNonlin	O
Enterprise	O
version	O
5.2	O
Model	O
200	O
and	O
Model	O
210	O
(	O
Certara	O
,	O
Princeton	O
,	O
NJ	O
)	O
.	O

The	O
primary	O
objectives	O
were	O
to	O
investigate	O
the	O
safety	O
and	O
tolerability	O
and	O
determine	O
the	O
preliminary	O
PK	O
of	O
CC-223	B-arm_description
administered	O
orally	O
.	O
Secondary	O
objectives	O
were	O
to	O
characterize	O
the	O
PK	O
of	O
M1	O
,	O
to	O
evaluate	O
the	O
inhibition	O
of	O
mTORC1	O
and	O
mTORC2	O
in	O
peripheral	O
blood	O
using	O
p4E	O
-	O
BP1	O
and	O
pAKT	O
as	O
biomarkers	O
,	O
and	O
to	O
evaluate	O
the	O
preliminary	O
efficacy	O
of	O
CC-223	B-arm_description
in	O
terms	O
of	O
tumor	O
response	O
,	O
PFS	B-arm_efficacy_metric
,	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

This	O
phase	B-study_type
1/2	I-study_type
study	I-study_type
was	O
not	O
powered	O
for	O
inferential	O
statistics	O
and	O
mostly	O
descriptive	O
statistics	O
were	O
used	O
.	O
All	O
patients	O
dosed	O
with	O
CC-223	B-arm_description
were	O
included	O
in	O
the	O
safety	O
analysis	O
.	O
The	O
efficacy	O
analysis	O
included	O
all	O
patients	O
completing	O
at	O
least	O
one	O
cycle	O
of	O
drug	O
who	O
had	O
both	O
baseline	O
and	O
one	O
post	O
-	O
baseline	O
tumor	O
efficacy	O
assessment	O
,	O
unless	O
otherwise	O
specified	O
.	O
Categorical	O
baseline	O
variables	O
including	O
tumor	O
type	O
-	O
specific	O
characteristics	O
were	O
summarized	O
using	O
frequency	O
counts	O
and	O
percentage	O
.	O
Continuous	O
demographic	O
and	O
baseline	O
characteristic	O
variables	O
were	O
summarized	O
by	O
descriptive	O
statistics	O
.	O
A	O
Wilcoxon	O
signed	O
rank	O
test	O
was	O
used	O
to	O
analyse	O
change	O
from	O
baseline	O
in	O
serum	O
hormone	O
levels	O
at	O
selected	O
scheduled	O
visits	O
.	O

Best	O
overall	O
tumor	O
response	O
by	O
investigator	O
assessment	O
was	O
summarized	O
using	O
frequency	O
tabulation	O
.	O
Waterfall	O
plots	O
were	O
used	O
to	O
show	O
best	O
percentage	O
change	O
from	O
baseline	O
in	O
the	O
sum	O
of	O
length	O
(	O
longest	O
diameter	O
)	O
of	O
target	O
lesions	O
.	O

Relationship	O
between	O
PFS	B-arm_efficacy_metric
and	O
NET	O
-	O
specific	O
assessments	O
such	O
as	O
serum	O
hormone	O
levels	O
and	O
carcinoid	O
symptoms	O
were	O
investigated	O
.	O
The	O
Kaplan	O
-	O
Meier	O
estimate	O
of	O
median	B-arm_efficacy_metric
PFS	B-arm_efficacy_metric
with	O
its	O
two	O
-	O
sided	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
was	O
provided	O
for	O
each	O
baseline	O
category	O
of	O
the	O
selected	O
biomarkers	O
.	O
Kaplan	O
-	O
Meier	O
plots	O
of	O
PFS	O
were	O
created	O
by	O
category	O
.	O
The	O
raw	O
P	O
value	O
of	O
the	O
log	O
rank	O
test	O
comparing	O
survival	O
distribution	O
of	O
PFS	O
between	O
categories	O
was	O
also	O
provided	O
.	O

Approximately	O
40	O
evaluable	O
patients	O
with	O
NET	O
were	O
planned	O
for	O
further	O
evaluation	O
of	O
safety	O
and	O
preliminary	O
antitumor	O
activity	O
.	O
Patients	O
could	O
receive	O
CC-223	B-arm_description
at	O
the	O
MTD	O
and/or	O
a	O
lower	O
dose	O
level	O
based	O
on	O
the	O
safety	O
,	O
PK	O
,	O
and	O
PD	O
data	O
from	O
the	O
dose	O
escalation	O
phase	O
[	O
13	O
]	O
.	O

Enrollment	O
and	O
tumor	O
response	O
rate	O
monitoring	O
were	O
based	O
on	O
Wald	O
's	O
sequential	O
analysis	O
[	O
15	O
]	O
.	O
Assuming	O
a	O
target	O
response	O
rate	O
of	O
20	O
%	O
for	O
the	O
tumor	O
type	O
of	O
interest	O
(	O
NET	O
)	O
,	O
based	O
on	O
the	O
sequential	O
design	O
,	O
with	O
80	O
%	O
power	O
to	O
identify	O
the	O
group	O
with	O
20	O
%	O
or	O
more	O
response	O
rate	O
at	O
5	O
%	O
significance	O
level	O
when	O
the	O
response	O
rate	O
is	O
at	O
10	O
%	O
,	O
the	O
enrollment	O
could	O
be	O
stopped	O
for	O
futility	O
when	O
there	O
was	O
no	O
responder	O
out	O
of	O
up	O
to	O
14	O
evaluable	O
patients	O
.	O

The	O
study	O
was	O
conducted	O
between	O
July	O
2011	O
and	O
October	O
2016	O
at	O
15	O
investigational	O
sites	O
.	O
From	O
a	O
total	O
of	O
58	O
screened	O
patients	O
,	O
47	O
met	O
all	O
eligibility	O
criteria	O
.	O
Of	O
those	O
,	O
the	O
first	O
24	O
started	O
CC-223	B-arm_description
at	O
the	O
MTD	O
of	O
45	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
day	I-arm_dosage
and	O
the	O
subsequent	O
23	O
started	O
at	O
30	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
day	I-arm_dosage
.	O
Median	O
age	O
was	O
63	O
years	O
(	O
min	O
-	O
max	O
:	O
35	O
-	O
79	O
years	O
)	O
(	O
Table	O
1	O
)	O
.	O
Men	O
comprised	O
40	O
%	O
of	O
the	O
population	O
;	O
92	O
%	O
of	O
patients	O
were	O
white	O
,	O
and	O
64	O
%	O
had	O
ECOG	O
performance	O
status	O
score	O
of	O
1	O
on	O
entry	O
.	O
Most	O
(	O
91	O
%	O
)	O
had	O
received	O
prior	O
SSA	O
therapy	O
and	O
43	O
%	O
had	O
received	O
additional	O
systemic	O
treatment	O
;	O
no	O
patient	O
received	O
prior	O
mTOR	O
inhibitor	O
therapy	O
;	O
however	O
,	O
one	O
patient	O
received	O
concomitant	O
treatment	O
with	O
everolimus	O
.	O
The	O
majority	O
(	O
57	O
%	O
)	O
had	O
midgut	O
,	O
followed	O
by	O
other	O
GI	O
(	O
23	O
%	O
)	O
tumors	O
,	O
and	O
53	O
%	O
reported	O
NET	O
-	O
related	O
symptoms	O
of	O
either	O
flushing	O
or	O
diarrhea	O
.	O
Eighteen	O
patients	O
(	O
38	O
%	O
)	O
withdrew	O
from	O
the	O
study	O
due	O
to	O
progression	O
of	O
their	O
disease	O
,	O
9	O
(	O
19	O
%	O
)	O
due	O
to	O
withdrawal	O
of	O
consent	O
,	O
8	O
(	O
17	O
%	O
)	O
due	O
to	O
adverse	O
events	O
,	O
2	O
patients	O
(	O
4	O
%	O
)	O
died	O
,	O
and	O
10	O
(	O
21	O
%	O
)	O
discontinued	O
for	O
other	O
reasons	O
.	O

Mean	O
percent	O
decrease	O
from	O
baseline	O
to	O
day	O
15	O
of	O
treatment	O
in	O
[	O
18	O
F]-FDG	O
PET	O
SUV	O
in	O
31	O
patients	O
was	O
32.0	O
%	O
(	O
standard	O
deviation	O
35.2	O
%	O
;	O
P<0.0001	O
,	O
Wilcoxon	O
signed	O
rank	O
test	O
)	O
.	O
Twentyone	O
patients	O
(	O
44.7	O
%	O
)	O
exhibited	O
at	O
least	O
a	O
15	O
%	O
reduction	O
in	O
uptake	O
and	O
18	O
(	O
38.3	O
%	O
)	O
had	O
at	O
least	O
a	O
25	O
%	O
reduction	O
in	O
SUV	O
.	O
These	O
metabolic	O
changes	O
did	O
not	O
correlate	O
strongly	O
with	O
subsequent	O
tumor	O
response	O
outcomes	O
using	O
RECIST	O
criteria	O
(	O
Fig	O
2	O
)	O
.	O

Of	O
the	O
47	O
patients	O
,	O
41	O
completed	O
at	O
least	O
one	O
cycle	O
of	O
CC-223	B-arm_description
,	O
had	O
at	O
least	O
one	O
restaging	O
,	O
and	O
were	O
thus	O
evaluable	O
for	O
efficacy	O
.	O
By	O
investigator	O
assessment	O
,	O
no	O
patient	O
had	O
a	O
complete	O
response	O
(	O
CR	O
)	O
,	O
3	O
patients	O
(	O
7.3	O
%	O
)	O
had	O
a	O
partial	O
response	O
(	O
PR	O
)	O
,	O
34	O
(	O
82.9	O
%	O
)	O
showed	O
stable	O
disease	O
(	O
SD	O
)	O
,	O
1	O
(	O
2.4	O
%	O
)	O
had	O
progressive	O
disease	O
(	O
PD	O
)	O
,	O
and	O
for	O
3	O
(	O
7.3	O
%	O
)	O
the	O
assessment	O
was	O
not	O
done	O
.	O
Thus	O
,	O
the	O
objective	O
response	O
rate	O
(	O
CR+PR	O
)	O
was	O
7.3	O
%	O
(	O
95	O
%	O
CI	O
1.5	O
-	O
19.9	O
%	O
)	O
and	O
the	O
disease	O
control	O
rate	O
(	O
CR+PR+SD	O
)	O
was	O
90.2	O
%	O
(	O
95	O
%	O
CI	O
76.9	O
-	O
97.3	O
%	O
)	O
.	O
It	O
is	O
noteworthy	O
that	O
tumor	O
shrinkage	O
of	O
any	O
magnitude	O
relative	O
to	O
baseline	O
was	O
observed	O
in	O
73.2	O
%	O
patients	O
(	O
95	O
%	O
CI	O
57.1	O
-	O
85.8	O
%	O
)	O
(	O
Fig	O
2	O
)	O
.	O
Duration	O
of	O
response	O
for	O
the	O
three	O
patients	O
with	O
PR	O
was	O
125	O
,	O
253	O
+	O
(	O
no	O
PD	O
reported	O
)	O
,	O
and	O
401	O
days	O
.	O
The	O
median	O
duration	O
of	O
SD	O
was	O
long	O
and	O
lasted	O
297	O
days	O
(	O
min	O
50	O
days	O
,	O
max	O
1519	O
days	O
)	O
.	O
Duration	O
of	O
SD	O
was	O
longer	O
than	O
a	O
year	O
in	O
17	O
patients	O
.	O
Median	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
for	O
the	O
treated	O
population	O
was	O
19.5	B-arm_efficacy_results
months	I-arm_efficacy_results
(	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
10.4	I-arm_efficacy_results
-	I-arm_efficacy_results
28.5	I-arm_efficacy_results
months	I-arm_efficacy_results
)	I-arm_efficacy_results
with	O
rates	B-arm_efficacy_results
at	I-arm_efficacy_results
6	I-arm_efficacy_results
and	I-arm_efficacy_results
10	I-arm_efficacy_results
months	I-arm_efficacy_results
of	I-arm_efficacy_results
85	I-arm_efficacy_results
%	I-arm_efficacy_results
and	I-arm_efficacy_results
64	I-arm_efficacy_results
%	I-arm_efficacy_results
,	O
respectively	O
;	O
median	O
OS	O
was	O
not	O
assessable	O
(	O
OS	O
rate	O
at	O
48	O
weeks	O
was	O
0.97	O
)	O
(	O
Fig	O
3	O
)	O
.	O

On	O
enrollment	O
,	O
carcinoid	O
-	O
related	O
flushing	O
and	O
diarrhea	O
were	O
reported	O
in	O
16	O
(	O
34	O
%	O
)	O
and	O
22	O
(	O
47	O
%	O
)	O
patients	O
,	O
respectively	O
,	O
with	O
both	O
reported	O
in	O
13	O
patients	O
(	O
28	O
%	O
)	O
.	O
Symptom	O
reduction	O
at	O
any	O
time	O
during	O
the	O
study	O
was	O
observed	O
for	O
flushing	O
in	O
8	O
(	O
50	O
%	O
)	O
patients	O
,	O
for	O
diarrhea	O
in	O
9	O
(	O
41	O
%	O
)	O
patients	O
,	O
and	O
for	O
both	O
symptoms	O
in	O
5	O
(	O
39	O
%	O
)	O
patients	O
.	O
An	O
ad	O
hoc	O
exploratory	O
analysis	O
suggested	O
that	O
patients	O
with	O
carcinoid	O
symptom	O
improvement	O
had	O
a	O
higher	O
PFS	B-arm_efficacy_metric
than	O
patients	O
without	O
improvement	O
(	O
median	O
survival	O
[	B-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
]	I-arm_efficacy_results
108	I-arm_efficacy_results
.	I-arm_efficacy_results
4	I-arm_efficacy_results
Among	O
the	O
35	O
patients	O
with	O
elevated	O
baseline	O
levels	O
in	O
at	O
least	O
one	O
hormone	O
,	O
a	O
�	O
50	O
%	O
decline	O
from	O
baseline	O
was	O
reported	O
for	O
CgA	O
(	O
7	O
patients	O
)	O
,	O
gastrin	O
(	O
6	O
patients	O
)	O
,	O
glucagon	O
(	O
3	O
patients	O
)	O
,	O
and	O
serotonin	O
(	O
2	O
patients	O
)	O
.	O
Sample	O
sizes	O
were	O
small	O
and	O
hormones	O
fluctuated	O
considerably	O
over	O
time	O
;	O
none	O
of	O
the	O
changes	O
from	O
baseline	O
were	O
statistically	O
significant	O
except	O
for	O
CgA	O
(	O
cycle	O
21	O
and	O
end	O
of	O
treatment	O
;	O
P	O
�	O
0.039	O
[	O
log	O
rank	O
text	O
]	O
for	O
each	O
cycle	O
)	O
and	O
serotonin	O
in	O
some	O
later	O
cycles	O
(	O
cycles	O
11,13,15,17,19,21,23,25	O
,	O
and	O
end	O
of	O
treatment	O
;	O
P	O
�	O
0.037	O
[	O
log	O
rank	O
test	O
]	O
for	O
each	O
cycle	O
)	O
.	O
One	O
responder	O
had	O
a	O
>	O
50	O
%	O
decline	O
in	O
CgA	O
,	O
and	O
one	O
responder	O
had	O
a	O
>	O
50	O
%	O
decline	O
in	O
gastrin	O
.	O
Too	O
few	O
patients	O
with	O
any	O
elevated	O
baseline	O
levels	O
had	O
sufficient	O
tumor	O
response	O
data	O
for	O
meaningful	O
correlative	O
analysis	O
.	O